Chardan lowered the firm’s price target on Metagenomi (MGX) to $17 from $21 and keeps a Buy rating on the shares after the company disclosed the termination of its collaboration with Moderna (MRNA) and the return to Metagenomi of global rights to its editing tech including base editing and RIGS. In addition to removing the Moderna collaboration from the firm’s model, the firm reduced its view on the odds of success for PH1 to 17.5% from 40% to reflect the increased uncertainty, the analyst tells investors. If Metagenomi chooses to advance PH1, the firm understands it would be using non-Moderna LNP and mRNA tech, so the mouse data generated by Moderna “may not necessarily reflect a future candidate profile,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi Reclaims Rights, Shifts Strategy Post-Moderna Partnership
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
- Metagenomi reports 2023 EPS ($20.05), consensus ($5.42)
- Metagenomi Reports Business Updates and Full Year 2023 Financial Results
- Lyft upgraded, Philip Morris downgraded: Wall Street’s top analyst calls